Quantum-Si Introduces Protein Barcoding Kit for Multiplexed Protein Screening
Quantum-Si (Nasdaq: QSI) has launched its new protein Barcoding Kit, designed to revolutionize protein research through multiplexed screening. The kit employs peptide barcodes for efficient protein analysis, particularly beneficial for biopharma research applications including lipid nanoparticle optimization and mRNA therapeutics evaluation. Key features include overnight workflow with minimal hands-on time, ability to detect low-abundance proteins, and relative quantitation across a broad dynamic range. The solution aims to reduce time and costs while maintaining high sensitivity for therapeutic development.
Quantum-Si (Nasdaq: QSI) ha lanciato il suo nuovo Barcoding Kit per le proteine, progettato per rivoluzionare la ricerca sulle proteine attraverso lo screening multiplexato. Il kit utilizza codici a barre peptidici per un'analisi efficace delle proteine, risultando particolarmente vantaggioso per le applicazioni di ricerca biopharma, tra cui l'ottimizzazione delle nanoparticelle lipidiche e la valutazione delle terapie a base di mRNA. Le caratteristiche principali includono un flusso di lavoro notturno con un tempo di intervento minimo, la capacit脿 di rilevare proteine a bassa abbondanza e la quantificazione relativa su un ampio intervallo dinamico. La soluzione mira a ridurre tempo e costi mantenendo un'elevata sensibilit脿 per lo sviluppo terapeutico.
Quantum-Si (Nasdaq: QSI) ha lanzado su nuevo Barcoding Kit de prote铆nas, dise帽ado para revolucionar la investigaci贸n proteica a trav茅s de la detecci贸n multiplexada. El kit emplea c贸digos de barras pept铆dicos para un an谩lisis eficiente de prote铆nas, siendo especialmente beneficioso para aplicaciones de investigaci贸n biopharma, incluida la optimizaci贸n de nanopart铆culas lip铆dicas y la evaluaci贸n de terapias con mRNA. Las caracter铆sticas clave incluyen un flujo de trabajo nocturno con un tiempo de manejo m铆nimo, la capacidad de detectar prote铆nas de baja abundancia y la cuantificaci贸n relativa en un amplio rango din谩mico. La soluci贸n busca reducir el tiempo y los costos mientras mantiene una alta sensibilidad para el desarrollo terap茅utico.
Quantum-Si (Nasdaq: QSI)電� 雼氨歆� 鞐瓣惮毳� 順侅嫚頃橁赴 鞙勴暣 靹り硠霅� 靸堧鞖� 氚旍綌霌� 韨ろ姼毳� 於滌嫓頄堨姷雼堧嫟. 鞚� 韨ろ姼電� 雼れ瓴�靷ゼ 韱淀暣 雼氨歆� 攵勳劃鞚� 須湪鞝侅溂搿� 靾橅枆頃橁赴 鞙勴暣 韼╉儉鞚措摐 氚旍綌霌滊ゼ 靷毄頃╇媹雼�. 鞚措姅 歆�歆� 雮橂吀鞛呾瀽 斓滌爜頇� 氚� mRNA 旃橂 韽夑皜毳� 韽暔頃� 靸濍獏瓿淀暀 鞐瓣惮 鞎犿攲毽紑鞚挫厴鞐� 韸鬼瀳 鞙犾澋頃╇媹雼�. 欤检殧 韸轨鞙茧電� 斓滌唽頃滌潣 鞛戩梾 鞁滉皠鞚� 鞖旉惮頃橂姅 鞎缄皠 鞛戩梾 頋愲, 鞝�雴嶋弰 雼氨歆� 韮愳 電ル牓, 氚� 雱撿潃 霃欖爜 氩旍渼鞐愳劀鞚� 靸侂寑 鞝曤焿頇旉皜 韽暔霅╇媹雼�. 鞚� 靻旊（靺橃潃 雴掛潃 臧愲弰毳� 鞙犾頃橂┐靹� 旃橂 臧滊皽鞚� 鞙勴暅 鞁滉皠瓿� 牍勳毄鞚� 欷勳澊電� 瓴冹潉 氇╉憸搿� 頃橁碃 鞛堨姷雼堧嫟.
Quantum-Si (Nasdaq: QSI) a lanc茅 son nouveau Kit de Barcoding pour les prot茅ines, con莽u pour r茅volutionner la recherche sur les prot茅ines gr芒ce au criblage multiplement. Le kit utilise des codes-barres peptidiques pour une analyse prot茅ique efficace, particuli猫rement b茅n茅fique pour les applications de recherche biopharmaceutique, y compris l'optimisation des nanoparticules lipidiques et l'茅valuation des th茅rapies bas茅es sur l'ARNm. Les caract茅ristiques cl茅s comprennent un flux de travail de nuit avec un temps d'intervention minimal, la capacit茅 de d茅tecter des prot茅ines 脿 faible abondance et la quantification relative sur une large plage dynamique. La solution vise 脿 r茅duire le temps et les co没ts tout en maintenant une haute sensibilit茅 pour le d茅veloppement th茅rapeutique.
Quantum-Si (Nasdaq: QSI) hat sein neues Barcoding Kit f眉r Proteine eingef眉hrt, das entwickelt wurde, um die Proteinforschung durch multiplexes Screening zu revolutionieren. Das Kit verwendet Peptid-Barcodes f眉r eine effiziente Proteinanalyse und ist besonders vorteilhaft f眉r biopharmazeutische Forschungsanwendungen, einschlie脽lich der Optimierung von lipidbasierten Nanopartikeln und der Evaluierung von mRNA-Therapeutika. Zu den wichtigsten Funktionen geh枚ren ein n盲chtlicher Arbeitsablauf mit minimalem Zeitaufwand, die F盲higkeit, Proteine mit niedriger Abundanz zu erkennen, und eine relative Quantifizierung 眉ber einen breiten dynamischen Bereich. Die L枚sung zielt darauf ab, Zeit und Kosten zu reduzieren, w盲hrend eine hohe Sensitivit盲t f眉r die therapeutische Entwicklung erhalten bleibt.
- Introduction of new product expanding company's portfolio
- Product offers time and cost efficiency benefits
- Technology addresses key biopharma research needs
- Solution provides broad dynamic range detection capability
- None.
Insights
The launch of QSI's protein Barcoding Kit represents a significant advancement in protein research technology, particularly for biopharma applications. The kit's key differentiators are its multiplexed screening capabilities and overnight workflow with minimal hands-on time, addressing major efficiency bottlenecks in therapeutic development.
The technology's ability to detect low-abundance proteins while providing relative quantitation across a broad dynamic range is particularly valuable for LNP optimization and mRNA therapeutic evaluation. This could accelerate drug development timelines and reduce costs for pharmaceutical companies. However, market adoption will depend on validation studies and competitive pricing against established protein analysis methods.
The offers a multiplexed solution for efficient protein screening using peptide barcodes, tailored to the needs of biopharma research. It supports critical applications such as optimizing lipid nanoparticle (LNP), evaluating mRNA therapeutics, and analyzing protein characteristics.
The kit reduces time and costs through streamlined workflows while delivering relative quantitation across a broad dynamic range. With an overnight workflow that requires less than an hour of hands-on time, it is designed to be sensitive enough to detect low-abundance proteins, providing researchers with an innovative tool for therapeutic development.
鈥淲e believe Quantum-Si鈥檚 protein Barcoding Kit represents a groundbreaking leap forward in protein research, combining multiplexed precision with effortless workflows to transform how biopharma tackles complex challenges. By enabling faster, more cost-effective analysis of protein and drug delivery systems, this innovation paves the way for breakthroughs in therapeutic development,鈥� said Jeff Hawkins, President and Chief Executive Officer of Quantum-Si.
For more information about Quantum-Si鈥檚 innovative solutions, visit .
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company鈩�, is focused on revolutionizing the growing field of proteomics. The Company鈥檚 Platinum庐 instrument enables Next-Gen Protein Sequencing鈩� that advances proteomic research, drug discovery, and diagnostics beyond what has been possible with existing proteomic tools. Learn more at or follow us on or .
Forward Looking Statements
This press release includes 鈥渇orward-looking statements鈥� within the meaning of the 鈥渟afe harbor鈥� provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as 鈥渆xpect,鈥� 鈥渆stimate,鈥� 鈥減roject,鈥� 鈥渂udget,鈥� 鈥渇orecast,鈥� 鈥渁nticipate,鈥� 鈥渋ntend,鈥� 鈥減lan,鈥� 鈥渕ay,鈥� 鈥渨ill,鈥� 鈥渃ould,鈥� 鈥渟hould,鈥� 鈥渂elieves,鈥� 鈥減redicts,鈥� 鈥減otential,鈥� 鈥渃ontinue,鈥� and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company鈥檚 expectations with respect to future performance and development and commercialization of products and services. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company鈥檚 control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company鈥檚 Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth profitably and retain its key employees; the Company鈥檚 ongoing leadership transitions; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company鈥檚 product development and commercialization activities; the commercialization and adoption of the Company鈥檚 existing products and the success of any product the Company may offer in the future; the potential attributes and benefits of the Company鈥檚 commercialized Platinum庐 protein sequencing instrument and kits and the Company鈥檚 other products once commercialized; the Company鈥檚 ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company鈥檚 ability to identify, in-license or acquire additional technology; the Company鈥檚 ability to maintain its existing lease, license, manufacture and supply agreements; the Company鈥檚 ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company鈥檚 products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others; the Company鈥檚 estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company鈥檚 financial performance; and other risks and uncertainties described under 鈥淩isk Factors鈥� in the Company鈥檚 most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and in the Company鈥檚 other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
View source version on businesswire.com:
Investor Contact
Jeff Keyes
Chief Financial Officer
ir@quantum-si.com
Media Contact
Katherine Atkinson, SVP, Commercial Marketing
media@quantum-si.com
Source: Quantum-Si Incorporated
FAQ
What is Quantum-Si's new Barcoding Kit used for?
What are the key features of QSI's protein Barcoding Kit?
How does the QSI Barcoding Kit improve protein research efficiency?
